Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

WuXi PharmaTech Reports Higher Q3

publication date: Nov 16, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

WuXi PharmaTech (药明康德), a bellwether for China’s CRO industry, reported a modest increase in Q3 revenues, but clearly feels the worst of the economic downturn is in the past. Revenues move up 10% to $70 million, and net income (non-GAAP) was 33% higher at $17.6 million. The company reiterated its guidance for 2009 revenues while raising its estimate for 2009 adjusted EBITDA. China-based Laboratory Services division is the company’s best performing segment. More details..

Stock Symbol: (NYSE: WX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...